2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Atherosclerosis D050197 85 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Endometriosis D004715 29 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Pregnancy Complications D011248 19 associated lipids
Down Syndrome D004314 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Angina, Unstable D000789 14 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Balazy M et al. Facile method for preparation of 2,3-dinor-6-keto PGF1 alpha, the major urinary metabolite of prostacyclin. 1988 Prostaglandins pmid:3070630
Falardeau P et al. Urinary levels of 2,3-dinor-6-oxo-PGF1 alpha: a reliable index of the production of PGI2 in the spontaneously hypertensive rat. 1985 Prostaglandins pmid:3890022
Sun FF et al. Preparation of two dinor-PGI2 metabolites from 6-keto-PGF1 alpha by Mycobacterium rhodochrous. 1980 Prostaglandins pmid:6258195
Vesterqvist O and Gréen K Development of a GC-MS method for quantitation of 2,3-dinor-6-keto-PGF1 alpha and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. 1984 Prostaglandins pmid:6548317
Stichtenoth DO et al. Increased total body synthesis of prostacyclin in rats with adjuvant arthritis. 1995 Nov-Dec Prostaglandins pmid:8838242
Schaefer WR et al. Urinary excretion of 2,3-dinor-6-keto-PGF1 alpha and 11-dehydro-TXB2 by the gravid spontaneously hypertensive rat. 1996 Prostaglandins pmid:8875634
Ylikorkala O et al. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. 1990 Prostaglandins pmid:2106714
Henriksson P et al. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo. 1990 Prostaglandins pmid:2106716
Grèen K et al. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). 1989 Prostaglandins pmid:2664901
Huang YS et al. Effect of indomethacin treatment on prostaglandin excretion and tissue phospholipid fatty acid composition in rats bearing mammotropic pituitary tumor, MtT-F4. 1986 Prostaglandins Leukot Med pmid:3532134
Martrat A et al. Altered systemic and tissue prostacyclin in cerulein induced acute pancreatitis in rats. 1992 Prostaglandins Leukot. Essent. Fatty Acids pmid:1384068
Hiramatsu M et al. Application of an alpha-sidechain length-specific monoclonal antibody to immunoaffinity purification and enzyme immunoassay of 2,3-dinor-6-keto-prostaglandin F1 alpha from human urine. 1994 Prostaglandins Leukot. Essent. Fatty Acids pmid:8171070
van der Weiden RM et al. Prostanoid excretion before in vitro fertilization relates to the likelihood of pregnancy. 1995 Prostaglandins Leukot. Essent. Fatty Acids pmid:8821123
Stichtenoth DO et al. Effects of intravenous oxygen on prostacyclin and thromboxane formation in patients with peripheral occlusive arterial disease. 2001 Prostaglandins Leukot. Essent. Fatty Acids pmid:11728174
Pancera P et al. Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. 1996 Prostaglandins Leukot. Essent. Fatty Acids pmid:8860111
Rossi P et al. Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. 1997 Prostaglandins Leukot. Essent. Fatty Acids pmid:9175173
Rossi P et al. Prostacyclin and thromboxane A2 synthesis are increased in acute lower limb ischaemia. 1996 Prostaglandins Leukot. Essent. Fatty Acids pmid:9014222
Hishinuma T et al. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. 2001 Prostaglandins Leukot. Essent. Fatty Acids pmid:11728171
Sinzinger H Comments on "Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications". 2002 Prostaglandins Leukot. Essent. Fatty Acids pmid:12445490
Delemarre FM et al. Urinary prostaglandin excretion in pregnancy: the effect of dietary sodium restriction. 2000 Prostaglandins Leukot. Essent. Fatty Acids pmid:11049696
Hishinuma T et al. Analysis of the thromboxane/prostacyclin balance in human urine by gas chromatography/selected ion monitoring: abnormalities in diabetics. 1996 Prostaglandins Leukot. Essent. Fatty Acids pmid:8888357
Mizugaki M et al. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. 1999 Prostaglandins Other Lipid Mediat. pmid:10593167
Hishinuma T et al. Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. 1999 Prostaglandins Other Lipid Mediat. pmid:10593168
Hoch B and Bernhard M Reduced prostacyclin to thromboxane A2 ratio is correlated with central apneas in preterm infants. 1999 Prostaglandins Other Lipid Mediat. pmid:10593170
Blatnik M and Steenwyk RC Quantification of urinary PGEm, 6-keto PGF(1alpha) and 2,3-dinor-6-keto PGF(1alpha) by UFLC-MS/MS before and after exercise. 2010 Prostaglandins Other Lipid Mediat. pmid:20416393
Lynch CM et al. The role of thromboxane A(2) in the pathogenesis of intrauterine growth restriction associated with maternal smoking in pregnancy. 2011 Prostaglandins Other Lipid Mediat. pmid:21723954
Rosenkranz B et al. Urinary and systemic metabolites of prostacyclin in the perfused rabbit kidney. 1982 Ren Physiol pmid:6750728
Vesterqvist O et al. Synthetic arterial grafts cause prolonged increase in the in vivo formation of thromboxane and prostacyclin in humans. 1987 Res Exp Med (Berl) pmid:3303204
Tanaka H et al. Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? 1999 Respir Med pmid:10653051
Vesterqvist O et al. In vivo production of thromboxane and prostacyclin in patients following total hip arthroplasty. 1988 Scand. J. Clin. Lab. Invest. pmid:3375779
Tohgi H et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. 1992 Stroke pmid:1412574
Numminen H et al. The effect of acute ingestion of a large dose of alcohol on the hemostatic system and its circadian variation. 2000 Stroke pmid:10835443
Morio H et al. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. 1993 Thromb. Haemost. pmid:8470052
Piret A et al. Increased platelet aggregability and prostacyclin biosynthesis induced by intense physical exercise. 1990 Thromb. Res. pmid:2140206
Reilly IA and FitzGerald GA Eicosenoid biosynthesis and platelet function with advancing age. 1986 Thromb. Res. pmid:3754355
Vesterqvist O et al. Thromboxane and prostacyclin formation in patients with deep vein thrombosis. 1987 Thromb. Res. pmid:3554598
Vericel E et al. Platelets and aging. I--Aggregation, arachidonate metabolism and antioxidant status. 1988 Thromb. Res. pmid:3129819
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Oates JA et al. Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man. 1984 Trans. Am. Clin. Climatol. Assoc. pmid:6433527
Jendryczko A and Tomala J An imbalance between the excretion of thromboxane and prostacyclin metabolites in women after the menopause. 1993 Zentralbl Gynakol pmid:8503234